TaiMed Biologics Net Assets
TaiMed Biologics net assets. Based on the latest financial reports, TaiMed Biologics (4147) has net assets worth NT$3.68 Billion TWD (≈ $115.83 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$4.50 Billion ≈ $141.81 Million USD) and total liabilities (NT$824.49 Million ≈ $25.98 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 4147 shareholders equity momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$3.68 Billion |
| % of Total Assets | 81.68% |
| Annual Growth Rate | 12.36% |
| 5-Year Change | 31.15% |
| 10-Year Change | -18.16% |
| Growth Volatility | 62.02 |
Net Assets of TaiMed Biologics (2009–2025)
Net assets of TaiMed Biologics from 2009 to 2025. This chart illustrates how TaiMed Biologics's net assets have evolved over time, based on quarterly financial data. See net asset quality index of TaiMed Biologics to measure how much of total assets are equity-financed.
Annual Net Assets for TaiMed Biologics (2009–2025)
The table below shows the annual net assets of TaiMed Biologics from 2009 to 2025. For live market cap and overall valuation, see TaiMed Biologics (4147) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | NT$3.86 Billion ≈ $121.54 Million |
-4.11% |
| 2024-12-31 | NT$4.02 Billion ≈ $126.74 Million |
+56.77% |
| 2023-12-31 | NT$2.57 Billion ≈ $80.85 Million |
-5.48% |
| 2022-12-31 | NT$2.71 Billion ≈ $85.53 Million |
-7.70% |
| 2021-12-31 | NT$2.94 Billion ≈ $92.67 Million |
-13.89% |
| 2020-12-31 | NT$3.42 Billion ≈ $107.62 Million |
-4.75% |
| 2019-12-31 | NT$3.59 Billion ≈ $112.99 Million |
-12.11% |
| 2018-12-31 | NT$4.08 Billion ≈ $128.56 Million |
-4.93% |
| 2017-12-31 | NT$4.29 Billion ≈ $135.23 Million |
-8.94% |
| 2016-12-31 | NT$4.71 Billion ≈ $148.51 Million |
-3.80% |
| 2015-12-31 | NT$4.90 Billion ≈ $154.37 Million |
+167.70% |
| 2014-12-31 | NT$1.83 Billion ≈ $57.67 Million |
+178.28% |
| 2013-12-31 | NT$657.73 Million ≈ $20.72 Million |
+1.94% |
| 2012-12-31 | NT$645.21 Million ≈ $20.33 Million |
-23.12% |
| 2011-12-31 | NT$839.24 Million ≈ $26.44 Million |
-19.39% |
| 2010-12-31 | NT$1.04 Billion ≈ $32.80 Million |
+74.06% |
| 2009-12-31 | NT$598.14 Million ≈ $18.84 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to TaiMed Biologics's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 130416300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
TaiMed Biologics Net Assets Breakdown (December 2025)
TaiMed Biologics net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | NT$5.16 Billion | 133.81% |
| Total Equity | NT$3.86 Billion | 100.00% |
TaiMed Biologics Competitors by Market Cap
The table below lists competitors of TaiMed Biologics ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
COINSHARES I. LS-000247
F:3TW
|
$472.53 Million |
|
Gansu Yatai Industrial Development Co Ltd
SHE:000691
|
$472.57 Million |
|
Studio Dragon Corporation
KQ:253450
|
$472.59 Million |
|
Aberdeen Standard Global Infrastructure Income Fund
NYSE:ASGI
|
$472.62 Million |
|
Zhejiang Liming Intelligent Manufacturing Co Ltd
SHG:603048
|
$472.42 Million |
|
Ce Link Ltd
SHE:300787
|
$472.41 Million |
|
Zhejiang Red Dragonfly Footwear Co Ltd
SHG:603116
|
$472.17 Million |
|
Integrated Electronic Systems Lab Co Ltd
SHE:002339
|
$472.09 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in TaiMed Biologics's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 4,022,909,000 to 3,857,689,000, a change of -165,220,000 (-4.1%).
- Net loss of 167,776,000 reduced equity.
- New share issuances of 8,780,000 increased equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-167.78 Million | -4.35% |
| Share Issuances | NT$8.78 Million | +0.23% |
| Other Changes | NT$-6.22 Million | -0.16% |
| Total Change | NT$- | -4.11% |
Book Value vs Market Value Analysis
This analysis compares TaiMed Biologics's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.92x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 3.23x to 3.92x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | NT$17.15 | NT$55.40 | x |
| 2018-12-31 | NT$16.23 | NT$55.40 | x |
| 2019-12-31 | NT$14.22 | NT$55.40 | x |
| 2020-12-31 | NT$13.54 | NT$55.40 | x |
| 2021-12-31 | NT$11.66 | NT$55.40 | x |
| 2022-12-31 | NT$10.75 | NT$55.40 | x |
| 2023-12-31 | NT$10.00 | NT$55.40 | x |
| 2024-12-31 | NT$14.73 | NT$55.40 | x |
| 2025-12-31 | NT$14.12 | NT$55.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently TaiMed Biologics utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -4.35%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -27.44%
- • Asset Turnover: 0.13x
- • Equity Multiplier: 1.25x
- Recent ROE (-4.35%) is above the historical average (-9.10%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -9.63% | 0.00% | 0.00x | 1.01x | NT$-961.66 Million |
| 2016 | -5.98% | -13581.98% | 0.00x | 1.02x | NT$-753.34 Million |
| 2017 | -12.22% | -6218.04% | 0.00x | 1.05x | NT$-953.78 Million |
| 2018 | -7.88% | -133.47% | 0.05x | 1.17x | NT$-729.76 Million |
| 2019 | -16.13% | -82.14% | 0.15x | 1.32x | NT$-937.29 Million |
| 2020 | -5.37% | -25.37% | 0.14x | 1.52x | NT$-524.89 Million |
| 2021 | -16.01% | -113.91% | 0.09x | 1.57x | NT$-765.08 Million |
| 2022 | -9.92% | -47.83% | 0.14x | 1.51x | NT$-540.78 Million |
| 2023 | -7.59% | -39.61% | 0.13x | 1.52x | NT$-451.42 Million |
| 2024 | -5.02% | -33.08% | 0.12x | 1.24x | NT$-604.12 Million |
| 2025 | -4.35% | -27.44% | 0.13x | 1.25x | NT$-553.54 Million |
Industry Comparison
This section compares TaiMed Biologics's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,264,704,500
- Average return on equity (ROE) among peers: 6.98%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| TaiMed Biologics (4147) | NT$3.68 Billion | -9.63% | 0.22x | $472.49 Million |
| Apex Biotechnology Corp (1733) | $896.93 Million | 0.00% | 0.25x | $91.32 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $2.09 Billion | 6.26% | 0.71x | $182.46 Million |
| Panion & BF Biotech Inc (1760) | $1.91 Billion | 4.04% | 0.69x | $133.58 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.82 Billion | 4.71% | 0.89x | $75.49 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $2.20 Billion | 13.43% | 0.26x | $108.60 Million |
| Level Biotechnology (3118) | $529.43 Million | 10.96% | 0.46x | $31.08 Million |
| GenMont Biotech Inc (3164) | $294.16 Million | -11.68% | 0.05x | $45.80 Million |
| Medigen Biotechnology (3176) | $807.90 Million | 0.00% | 0.08x | $141.32 Million |
| Sagittarius Life Science (3205) | $714.71 Million | 42.07% | 0.58x | $94.17 Million |
| Genovate Biotechnology Co Ltd (4130) | $1.38 Billion | 0.03% | 0.10x | $115.03 Million |
About TaiMed Biologics
TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. The company develops and markets Trogarzo IV infusion and Trogarzo IV push, a monoclonal antibody for HIV treatment. It is also developing TMB-365, a monoclonal antibody used for HIV treatment and prevention which has completed a phase-1 clinica… Read more